Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma

The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dung-Tsa, Davis-Yadley, Ashley H., Huang, Po-Yu, Husain, Kazim, Centeno, Barbara A., Permuth-Wey, Jennifer, Pimiento, Jose M., Malafa, Mokenge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527782/
https://www.ncbi.nlm.nih.gov/pubmed/26247463
http://dx.doi.org/10.1371/journal.pone.0133562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527782/
https://www.ncbi.nlm.nih.gov/pubmed/26247463
http://dx.doi.org/10.1371/journal.pone.0133562

Ejemplares similares